

15 January 2020
EMA/HMPC/638245/2018
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Aesculus hippocastanum* L., semen

Final – Revision 1

The European Medicines Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Bisler H, Pfeifer R, Klüken N and Pauschinger P. Wirkung von Rosskastaniensamenextrakt auf die transkapilläre Filtration bei chronischer venöser Insuffizienz. *Deutsche Medizinische Wochenschrift* 1986, 111:1321–1329

Blaschek W, Hänsel R, Keller K, Reichling J, Rimpler H, Schneider G, editors. Hagers Handbuch der Pharmazeutischen Praxis. Drogen A-D. Vol 4. 5th ed. Springer-Verlag, Berlin-Heidelberg 1992

Bombardelli E, Morazzoni P and Griffini A. *Aesculus hippocastanum* L. *Fitoterapia* 1996, 67:483–511

Bradley P. British Herbal Compendium Vol. 2. *British Herbal Medicine Association*, 2006

Brunner F, Hoffmann C and Schuller-Petrovic S. Responsiveness of human varicose saphenous veins to vasoactive agents. *Journal of Clinical Pharmacology* 2001, 51:219–224

Bässler D, Okpanyi S, Schrödter A, Loew D, Schürer M, Schulz H-U. Bioavailability of β -aescin from horse chestnut seed extract: comparative clinical studies of two galenic formulations. *Advances in Therapy* 2003, 20(5):295–304

Cloarec M. Study on the effect of a new vasoprotective Venostasin administered over a period of 2 months in chronic venous insufficiency of the lower limb (data from 1992). Data on file. Unpublished

CosIng [The European Commission database with information on cosmetic substances and ingredients (contained in the Cosmetics Regulation EC No 1223/2009, Cosmetics Directive 76/768/EEC and Inventory of Cosmetic Ingredients)]. Available at: <http://ec.europa.eu/consumers/cosmetics/cosing/>. Accessed March 2018

Diehm C, Trampish HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. *Lancet* 1996, 347:292–294

Diehm C, Schmidt C. Venostasin retard gegen Plazebo and Kompression bei Patienten mit CVI II/IIIa. Final Study Report. Klinge Pharma GmbH Munich, Germany. Reported in: Ottillinger B, Greeske K. *BMC Cardiovascular Disorders* 2001, 1-5

Diehm C, Vollbrecht D, Amendt K, Comberg HU. Medical edema protection—clinical benefit in patients with chronic deep vein incompetence. A placebo controlled double blind study. *VASA* 1992, 21(2):188–192

Dittgen M, Zimmermann H, Wober W, Höflich C, Breitsbarth H, Timpe C. Untersuchung der Bioverfügbarkeit von β -aescin nach oraler Verabreichung verschiedener Darreichungsformen. *Pharmazie* 1996, 51:608–610

Draft monograph intended for inclusion in the European Pharmacopoeia. Horse-chestnut. *Pharmeuropa* 1995, 7

Draft monograph intended for inclusion in the European Pharmacopoeia. Horse-chestnut dry extract, standardised. *Pharmeuropa* 1996, 8

Edem E, Kahyaoglu B, Çakar MA. Acute effusive pericarditis due to horse chestnut consumption. *American Journal of Case Reports* 2016, 17:305-308

Ehringer H. Zum venentonisierenden Prinzip des Roskastanienextraktes. *Die Medizinische Welt* 1968, 19:1781–1785

Enghofer E, Seibel K, Hammersen F. Die antiexsudative Wirkung von Roskastanienextrakt. *Die Therapiewoche* 1984, 34:4130–4144

Erdlen F. Klinische Wirksamkeit von Venostasin retard im Doppelblindversuch. *Die Medizinische Welt* 1989, 40:994–996

Erlor M. Roskastanienextrakt bei der Therapie peripherer Ödeme—ein klinischer Therapievergleich. *Die Medizinische Welt* 1991, 42:593–596

Ernst E, et al. *The Desktop Guide to Complementary and Alternative Medicine*. Mosby, 2001

ESCOP Monographs. ESCOP, the European Scientific Cooperative on Phytotherapy, Exeter, UK, 2003

European Pharmacopoeia 9th ed. Horse-chestnut–Hippocastani semen. Council of Europe 01/2017:1830

European Pharmacopoeia 9th ed. Horse-chestnut dry extract, standardised–Hippocastani seminis extractum siccum normatum. Council of Europe 01/2017:1829

Facino RF, Carini M, Stefani R, Aldini G, Saibene L. Anti-elastase and anti-hyaluronidase activities of saponins and sapogenins from *Hedera helix*, *Aesculus hippocastanum* and *Ruscus aculeatus*: factors contributing to their efficacy in the treatment of venous insufficiency. *Archiv der Pharmazie (Weinheim)* 1995, 328(10):721–724

Friederich HC, Vogelsberg H, Neiss A. Ein Beitrag zur Bewertung von intern wirksamen Venenpharmaka. *Zeitschrift für Hautkrankheiten* 1978, 53:369–374

Felixsson E, Persson IA, Eriksson AC, Persson K. Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5-HT(2A) receptors: an *in vitro* study. *Phytother Res* 2010, 24(9):1297–1301

Guillaume M, Padioleau F. Veinotonic effect, vascular protection, antiinflammatory and free radical scavenging properties of horse chestnut extract. *Arzneimittel-Forschung/Drug Research* 1994, 44(1):25–35

- Hartleb M, Gutkowski K. Unexpected liver cirrhosis in a young patient with long-term use of the horse chestnut seed extract. *Gazz Med Ital–Arch Sci Med* 2015, 174:141-142
- Hitzenberger, G. Die therapeutische Wirksamkeit des Rosskastaniensamenextraktes. *Wiener Medizinische Wochenschrift* 1989, 139:385–389
- Huang Y, Zheng S-L, Zhu H-Y, Xu Z-S, Xu R-A. Effects of aescin on cytochrome P450 enzymes in rats. *Journal of Ethnopharmacology* 2014, 151(1):583-590
- Iannitti T, Rottigni V, Palmieri B. Corticosteroid transdermal delivery to target swelling, edema and inflammation following facial rejuvenation procedures. *Drug Des Devel Ther* 2013, 7:1035-1041
- Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, *et al.* Assessing the quality of reports of randomised clinical trials: is blinding necessary? *Controlled Clinical Trials* 1996, 17(1):1–12
- Kalbfleisch W, Pfalzgraf H. Ödemprotektiva, Äquipoternite Dosierung-Roskastaniensamenextrakt und O-β-Hydroxyethylrutoside im Vergleich. *Therapiewoche* 1989, 39:3703–3707
- Koch R. Comparative study of Venostasin and pycnogenol in chronic venous insufficiency. *Phytotherapie Research* 2002, 16(1):1–5
- von Kreybig T, Prectel K. Toxizitäts-und Fertilitätsstudien mit Aescin bei der Ratte. *Arzneimittel-Forschung/Drug Research* 1977, 27:1465–1466
- Kunz K, Lorkowski G, Petersen G, Samcova E, Schaffler K, Wauschkuhn CH. Bioavailability of escin after administration of two oral formulations containing Aesculus extract. *Arzneimittel-Forschung/Drug Research* 1998, 48(8):822–825
- Li C, Liu Z, Gao Y, Liu K. Investigation of blood toxicity in association with aescin (the horse chestnut seed extract). *Toxicology Letters* 2006, 164S:S90
- Liehn HD, Franco PA, Hampel H, Hofrichter G. A toxicological study of extractum hippocastani semen (EHS). *Panminerva Medica* 1972, 14(3):84–91
- Liu L, Wu X, Wu D, Wang Y, Li P, Sun Y, *et al.* A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of esin Ia and Ib in human plasma: application to a pharmacokinetic study after intravenous administration. *Biomedical Chromatography* 2010, 24:1309-1315
- Loew D, Schrödter A, Schwankl W, März RW. Measurement of the bioavailability of aescin-containing extracts. *Methods and Findings in Experimental Clinical Pharmacology* 2000, 22(7):537–542
- Lochs H, Baumgartner H, Konzett H. Zur Beeinflussung des Venentonus durch Roßkastaniensamenextrakt. *Arzneim-Forsch/Drug Res* 1974, 24:1347-1350
- Lohr E, Garanin G, Jesau P, Fischer H. Ödempräventive Therapie bei chronischer Veneninsuffizienz mit Ödemneigung. *Münchener Medizinische Wochenschrift* 1986, 128:579–581
- Longiave D, Omini C, Nicosia S, Berti F. The mode of action on isolated veins: relationship with PGF2α. *Pharmacological Research Communications* 1978, 10(2):145–152
- Lorenz D, Marek ML. Das therapeutisch wirksame Prinzip der Rosskastanie (*Aesculus hippocastanum*). *Arzneimittel-Forschung/Drug Research* 1960, 10:263–272
- Mills S, Bone K. Principles and Practice of Phytotherapy. Churchill Livingstone, 2000

- Montopoli M, Frolidi G, Comelli MC, Prosdocimi M, Caparotta L. Aescin protection of human vascular endothelial cells exposed to cobalt chloride mimicked hypoxia and inflammatory stimuli. *Planta Medica* 2007, 73:285–288
- Morales Paris CA, Barros Soares RM. Eficácia e segurança do extrato seco da semente de castanha-da Índia no tratamento da insuficiência venosa crônica de membros inferiores. *Revista Brasileira de Medicina* 1993, 50:1563–1565
- Nehring U. Zum venentonisierenden Prinzip des Rosskastanienextractes. Wirkung von Rosskastanienextrakt und von Aescin auf Venenkapazität, Venentonus und Durchblutung der Extremitäten. *Die Medizinische Welt* 1966, 17:1662–1665
- Neiss A, Böhm C. Zum Wirksamkeitsnachweis von Rosskastaniensamenextrakt beim varikösen Symptomenkomplex. *Münchener Medizinische Wochenschrift* 1976, 118:213–216
- Newall CA, Anderson LA, Phillipson JD. Herbal Medicines. A guide for health-care professionals. The Pharmaceutical Press, 1996
- Oschmann R, Biber A, Lang F, Stumpf H, Kunz K. Pharmakokinetik von β -aescin nach Gabe verschiedener Aesculus-Extrakt enthaltender Formulierungen. *Pharmazie* 1996, 51:577–581
- Pauschinger P, Wörz E, Zwerger E. Die Messung des Filtrationskoeffizienten am menschlichen Unterschenkel und seine pharmakologische Beeinflussung. *Die Medizinische Welt* 1953, 32:55–58
- Pharmeuropa 26.3. Note on the monographs Horse-chestnut and Horse-chestnut dry extract, standardised. August 2014, pp. 182–194
- Pilz E. Ödeme bei Venenerkrankungen. *Die Medizinische Welt* 1990, 41:1143–1144
- Pitsch F. VEIN CONSULT Program: interim results from the first 70 000 screened patients in 13 countries. *Phlebology* 2012, 19(3):132–137
- Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. *Cochrane Database of Systematic Reviews* 2006, Issue 1, Art No.: CD003230
- Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. *Cochrane Database Syst Rev* 2012; 11:CD003230.
- Raffetto JD, Khalil RA. Ca²⁺-dependent contraction by the saponoside escin in rat vena cava: Implications in venotonic treatment of varicose veins. *Journal of Vascular Surgery* 2011, 54(2):489–496
- Rehn D, Unkauf M, Klein P, Jost V, Lückner PW. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency. *Arzneimittel-Forschung/Drug Research* 1996, 46(1):483–487
- Renaudin JM, Beaudouin E, Ponvert C, Demoly P, Moneret-Vautrin D-A. Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010. *Allergy* 2013, 68:929–937
- Reynolds JEF, Prasad AB. Martindale the Extra Pharmacopoeia. 28th Ed. The Pharmaceutical Press, 1982
- Rote Liste® Arzneimittelverzeichnis für Deutschland. Rote Liste® Service GmbH Frankfurt/M. (Hrsg.), ECV Aulendorf 1980
- Rudofsky G, Neiss A, Otto K, Seibel K. Ödemprotektive Wirkung und klinische Wirksamkeit von Rosskastaniensamenextrakt im Doppelblindversuch. *Phlebologie und Proktologie* 1986, 15:47–54

- Schimmer O, Krüger A, Paulini H, Haefele F. An evaluation of 55 commercial plant extracts in the Ames mutagenicity test. *Pharmazie* 1994, 49:448–451
- Schrader E, Schwankl W, Sieder C, Christoffel V. Vergleichende Untersuchung zur Bioverfügbarkeit von β -aescin nach oraler Einmalverabreichung zweier Rosskastaniensamenextrakt enthaltender, galenisch unterschiedlicher Darreichungsformen. *Pharmazie* 1995, 50:623–627
- Schrödter A, Loew D, Schwankl W, Rietbrock N. Zur Validität radioimmunologisch bestimmter Bioverfügbarkeitsdaten von β -aescin in Rosskastaniensamenextrakten. *Arzneimittel-Forschung/Drug Research* 1998, 48:905–910
- Siebert U, Brach M, Sroczynski G, Überla K. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomised controlled trials and large observational studies. *International Angiology* 2002, 21:305–315
- Sirtori CE. Aescin: pharmacology, pharmacokinetics and therapeutic profile. *Pharmacological Research* 2001, 44:183–193
- Snow A, Halpenny D, McNeill G, Torreggiani WC. Life-threatening rupture of a renal angiomyolipoma in a patient taking over-the-counter horse chestnut seed extract. *J Emerg Med* 2012, 43(6):401–403
- Steinegger E, Hänsel R. *Lehrbuch der Pharmakognosie*. Springer Verlag, 1972
- Steiner M, Hillemanns HG. Untersuchung zur oedemprotektiven Wirkung eines Venentherapeutikums. *Münchener Medizinische Wochenschrift* 1986, 128:551–552
- Steiner M, Hillemanns HG. Venostasin retard in the management of venous problems during pregnancy. *Phlebology* 1990, 5:41–44
- Takegoshi K, Tohyama T, Okuda K, Suzuki K, Ohta G. A case of Venoplast-induced hepatic injury. *Gastroenterol Jpn* 1986, 21(1):62–65
- Wang T, Zhao S, Wang Y, Yang Y, Yao L, Chu L, *et al.* Protective effects of escin against indomethacin-induced gastric ulcer in mice. *Toxicol Mech Methods* 2014, 24(8):560–566
- Widmer LK, Stähelin HB. *Peripheral venous disorders* Basel III. Bern: Huber 1978
- Wren RC. *Potter's new cyclopaedia of botanical drugs and preparations*. Saffron Walden the C.W. Daniel Company, 1988
- Wu X, Liu L, Zhang M, Wu D, Wang Y, Sun Y, *et al.* Simultaneous analysis of isomers of escin saponins in human plasma by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study after oral administration. *Journal of Chromatography B* 2010, 878:861–867
- Wulff G, Tschesche R. Über Triterpene-XXVI. Über die Struktur der Rosskastaniensaponine (Aescin) und die Aglykone verwandter Glykoside. *Tetrahedron* 1969, 25:415–436
- Zaj CM, Winiewski M, Sein AJ. [Intoxication by powdered seeds of horse chestnut (*Aesculus hippocastanum*) used nasally as snuff-a case report]. *In Polish Przegl Lek.* 2014, 71(9):502–503